Medical Food (US) and FSMP (EU)Medical Food and EU Food for Special Medical Purposes Framework
Medical food in the US and food for special medical purposes (FSMP) in the EU/UK are both food-law categories, not drug approvals — which is exactly why their compositional, labelling and supervision rules carry so much of the regulatory weight.

On this page · 10 sections
- 1The US statutory definition: a 1988 orphan-drug add-on, not a food-labelling invention
- 2FDA's narrow reading of the category, and what it excludes
- 3Not a drug, no premarket approval — and the compliance gap that creates
- 4FDA's guidance history: 2007, 2013/2016 drafts, and the 2023 third edition
- 5What FDA warning letters about medical foods actually target
- 6The EU framework: Regulation (EU) 609/2013 and its three replaced product categories
- 7Delegated Regulation (EU) 2016/128: FSMP's compositional categories and mandatory warnings
- 8Notification duties and the FSMP-classification grey zone
- 9Post-Brexit position: retained law in Great Britain, EU law under the Windsor Framework in Northern Ireland
- 10Why medical food manufacturing runs food GMP plus tighter specification control
How does Medical Food (US) and FSMP (EU) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01The US statutory definition: a 1988 orphan-drug add-on, not a food-labelling invention
The term "medical food" entered US law through Section 5(b) of the Orphan Drug Act of 1988, codified at 21 U.S.C. 360ee(b)(3), which Congress wrote to authorise federal grants defraying the cost of developing medical foods for rare diseases — alongside grants for rare-disease drugs and devices. The definition it created has outlasted the funding provision and become the operative legal test for the category: a medical food is "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation." FDA's Medical Foods Guidance Documents & Regulatory Information page quotes this definition as the starting point for how the agency regulates the category.
FDA's own labelling regulation — 21 CFR 101.9(j)(8), part of the general nutrition-labelling rule for food — restates and operationalises that statutory definition as one of the listed exemptions from standard nutrition labelling. FDA's enforcement letters set out the regulatory test in full: a food is considered a medical food only if it is a specially formulated and processed product (not a naturally occurring foodstuff used in its natural state) for the partial or exclusive feeding of a patient by means of oral intake or enteral feeding tube; it is intended for the dietary management of a patient who, because of therapeutic or chronic medical needs, has limited or impaired capacity to ingest, digest, absorb or metabolise ordinary foodstuffs or certain nutrients, or who has other special medically determined nutrient requirements, the dietary management of which cannot be achieved by modification of the normal diet alone; it provides nutritional support specifically modified for the management of the unique nutrient needs resulting from the specific disease or condition, as determined by medical evaluation; it is intended to be used under medical supervision; and it is intended only for a patient receiving active and ongoing medical supervision wherein the patient requires medical care on a recurring basis for, among other reasons, instructions on the use of the medical food. These five criteria read conjunctively — a product that fails any one of them is not, for labelling purposes, a medical food.
02FDA's narrow reading of the category, and what it excludes
FDA has consistently applied the medical-food definition narrowly, and its public guidance material — including the Guidance for Industry: Frequently Asked Questions About Medical Foods, now in a third edition dated March 2023 — spends most of its length explaining what does not qualify rather than what does. The agency's recurring position is that the "distinctive nutritional requirements" element is doing real work: the condition must create a nutrient need that medical evaluation has established and that cannot be met by ordinary dietary modification, not merely a need that a product's marketing asserts. A food aimed at a disease where diet simply needs tightening, or where a supplement might plausibly help symptoms, is not for that reason a medical food.
The category's clearest, most litigated applications are inborn errors of metabolism — phenylketonuria (PKU), maple syrup urine disease, urea cycle disorders, and similar conditions where a specific nutrient (phenylalanine, branched-chain amino acids, certain proteins) must be tightly restricted or substituted and where normal foods genuinely cannot achieve the needed dietary management. FDA's enforcement letters repeatedly draw the contrast with products that are instead ordinary foods, fibre supplements, or general nutritional support items relabelled with medical-food language because that framing avoids nutrition-labelling and health-claim constraints that would otherwise apply.
Two structural points follow from the Orphan Drug Act's wording and FDA's reading of it. First, medical food must be formulated for enteral use — oral intake or a feeding tube — which excludes parenteral (intravenous) nutrition products from the definition regardless of how disease-specific their formulation is. Second, because a medical food is, by statutory and regulatory definition, a food rather than a drug, it is not subject to drug premarket approval: there is no FDA approval, clearance, or authorisation process for a medical food equivalent to an NDA or 510(k), and FDA does not pre-review medical food formulations before marketing.
03Not a drug, no premarket approval — and the compliance gap that creates
Because medical foods are regulated as foods, they are subject to the general food-safety and labelling provisions of the Federal Food, Drug, and Cosmetic Act — adulteration and misbranding provisions, facility registration, and current good manufacturing practice for food — rather than to the drug approval pathway. There is no FDA premarket review of a medical food's formulation, no requirement to file an application demonstrating safety and efficacy before marketing, and no FDA-assigned approval number a manufacturer can point to. This is the trade-off at the centre of the category: the absence of a premarket gate makes medical foods faster and cheaper to bring to market than a drug, but it also means the entire legal basis for calling a product a medical food rests on the manufacturer correctly meeting the five-part 21 CFR 101.9(j)(8) test on an ongoing, self-assessed basis, with FDA checking that assessment only after the fact, through inspection and labelling review.
That after-the-fact structure is precisely what drives the warning-letter pattern described below: because there is no premarket checkpoint, the first point at which FDA typically engages with a specific product's medical-food status is a facility inspection or a labelling/marketing review that happens once the product is already on the market and, in several documented cases, already generating consumer purchases outside any physician relationship.
04FDA's guidance history: 2007, 2013/2016 drafts, and the 2023 third edition
FDA's primary vehicle for explaining its interpretation of the medical-food definition is a Guidance for Industry titled Frequently Asked Questions About Medical Foods, first issued in May 2007, revised to a second edition in May 2016 (following a 2013 draft that circulated for comment), and most recently updated to a third edition in March 2023. Like all FDA guidance documents, it carries the standard disclaimer that it "represents the Food and Drug Administration's current thinking on this topic," does not create or confer rights, and does not bind FDA or the public — a manufacturer may use an alternative approach provided it satisfies the underlying statute and regulation.
The FAQ guidance's substantive content works through the statutory and regulatory definitions in Q&A form, addressing recurring industry questions such as whether a product aimed at a common condition (rather than a rare disease) can qualify as a medical food, whether an over-the-counter product sold without physician involvement can meet the "medical supervision" criterion, and how FDA treats disease categories — obesity, diabetes, and general malnutrition among them — where the agency has stated that ordinary dietary modification can typically meet nutritional needs, making the distinctive-nutritional-requirements criterion correspondingly harder to satisfy.
05What FDA warning letters about medical foods actually target
FDA's published warning letters to medical-food marketers show a consistent enforcement pattern. In a 26 December 2013 letter to Accera, Inc., FDA reviewed the labelling and website for the Axona product, marketed as a "medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease," and determined the product was misbranded under Section 403(a)(1) of the FD&C Act [21 U.S.C. 343(a)(1)] because its labelling was false and misleading in representing it as a medical food when it did not meet the statutory definition in 21 U.S.C. 360ee(b)(3) or the criteria in 21 CFR 101.9(j)(8). In a 1 September 2017 letter to ND Labs, Inc., FDA made the identical finding against several products marketed and labelled as medical foods that the agency concluded did not satisfy either the statutory or regulatory test.
Reading across these letters, the recurring factual themes are: (1) the targeted disease or condition is one FDA considers manageable through ordinary diet modification, so the "distinctive nutritional requirements" criterion is not met; (2) the product is sold through retail or direct-to-consumer channels without the ongoing, recurring physician relationship the regulation requires, so the "medical supervision" criterion is not met; and (3) the product's formulation is not shown to be specifically modified to address a disease-specific nutrient need established by medical evaluation, as opposed to a general nutritional-support rationale. Because the underlying violation is misbranding rather than a facility or process defect, the corrective action FDA typically seeks is relabelling or reclassification of the product — as a conventional food, a dietary supplement, or (where disease claims persist) scrutiny as an unapproved drug — rather than a batch recall for a quality failure.
06The EU framework: Regulation (EU) 609/2013 and its three replaced product categories
The EU's equivalent category sits inside Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013, titled "on food intended for infants and young children, food for special medical purposes, and total diet replacement for weight control," which the EUR-Lex record confirms applies from 20 July 2016 and repealed the earlier Framework Directive 2009/39/EC together with several product-specific directives, including the FSMP-specific Commission Directive 1999/21/EC. Article 1 establishes compositional and information requirements across four food categories — infant and follow-on formula; processed cereal-based food and baby food; food for special medical purposes; and total diet replacement for weight control — and Article 1(2) establishes a Union (now, post-Brexit, a Great Britain) list of substances that may be added to those categories.
Regulation 609/2013 sets the general compositional and information requirements and the overarching principle — in Article 9 — that these foods must be safe, suitable, and formulated for the specific nutritional requirements of the people they are intended for, while leaving the detailed, category-specific compositional and labelling rules to be filled in by delegated acts. For FSMP, that delegated act is Commission Delegated Regulation (EU) 2016/128.
07Delegated Regulation (EU) 2016/128: FSMP's compositional categories and mandatory warnings
Commission Delegated Regulation (EU) 2016/128 of 25 September 2015 supplements Regulation (EU) No 609/2013 with the specific compositional and information requirements for food for special medical purposes. Its Article 1 states plainly that FSMP may only be placed on the market if it complies with the regulation, and Article 2 splits FSMP into three compositional categories: nutritionally complete food with a standard nutrient formulation that, used as instructed, may constitute the sole source of nourishment for the people it is intended for; nutritionally complete food with a nutrient-adapted formulation specific to a disease, disorder, or medical condition, which may likewise serve as a sole source of nourishment; and nutritionally incomplete food, with either a standard or nutrient-adapted formulation, that is not suitable as a sole source of nourishment.
The regulation also layers on labelling obligations beyond the general EU food information rules in Regulation (EU) No 1169/2011. The EUR-Lex summary of the delegated regulation confirms it bans nutrition and health claims on FSMP, and requires specific statements or warnings on the label — preceded by the words "important notice" or an equivalent phrasing — including that the product must be used under medical supervision. Where the FSMP is intended for infants, the delegated regulation also extends the stricter advertising, labelling, and presentation rules that otherwise apply to infant formula, and extends the EU's tighter pesticide-residue limits for infant and young-child FSMP.
| FSMP category (Art. 2, Reg. 2016/128) | Can it be a sole source of nourishment? | Typical use case |
|---|---|---|
| Nutritionally complete, standard formulation | Yes, as instructed | General enteral feeding need without a disease-specific nutrient restriction |
| Nutritionally complete, nutrient-adapted formulation | Yes, as instructed | Disease-, disorder-, or condition-specific feeding (e.g. an inborn error of metabolism) |
| Nutritionally incomplete, standard or nutrient-adapted | No | Supplementary or partial dietary management alongside other nutrition |
08Notification duties and the FSMP-classification grey zone
Unlike dietary supplements in several EU Member States, FSMP does not go through a premarket authorisation process at EU level; instead, Article 9 of Delegated Regulation (EU) 2016/128 requires the food business operator to notify the competent authority of each Member State (in the GB-adapted text, each part of Great Britain) where the product is marketed, by sending that authority a model of the product's label and any other information the authority reasonably requests to establish compliance. This is a notification regime, not an approval regime — the product can be placed on the market on the operator's own classification, with the competent authority free to query or challenge that classification afterwards.
That self-classification structure is precisely why the European Commission issued a dedicated Notice on the classification of Food for Special Medical Purposes (2017/C 401/01), which works through the FSMP definition in detail — the boundary between FSMP and medicinal products, what "specially processed or formulated" means, the requirement that FSMP be used under medical supervision, and the concepts of "dietary management" and "modification of the normal diet" that determine whether a condition's nutrient needs are genuinely incapable of being met by food supplements or fortified foods alone. The Notice also sets out what evidence a food business operator should hold to demonstrate a product is correctly placed on the market as FSMP, reflecting the same after-the-fact verification dynamic seen in the US system: there is no EU premarket sign-off, so the operator's own dossier is what a competent authority will test the classification against if queried.
09Post-Brexit position: retained law in Great Britain, EU law under the Windsor Framework in Northern Ireland
Since the end of the UK–EU transition period on 31 December 2020, Regulation (EU) No 609/2013 and Commission Delegated Regulation (EU) 2016/128 have applied in Great Britain as retained EU law, carried onto the UK statute book under the European Union (Withdrawal) Act 2018 and subsequently amended — for GB-specific terminology and institutional references — by the Nutrition (Amendment etc.) (EU Exit) Regulations 2019 and 2020. Those EU Exit instruments transferred the Commission's former rule-making functions on nutrition law to the competent authorities for each GB nation: the Secretary of State for England, Welsh Ministers for Wales, and the equivalent Scottish authority, with Food Standards Scotland supporting that function. The legislation.gov.uk text of Delegated Regulation (EU) 2016/128's Article 9, for example, now reads "the competent authority of each part of Great Britain" and lists the Secretary of State, the Welsh Ministers, and the corresponding Scottish competent authority as the respective notification recipients.
Northern Ireland sits on a different footing. GOV.UK's nutrition legislation information sheet confirms that, under the Protocol on Ireland/Northern Ireland (now operating under the Windsor Framework), EU legislation relating to nutrition — including the categories listed in the Protocol's Annex 2 — continues to apply directly in Northern Ireland rather than following the GB-amended retained-law text. For an FSMP manufacturer supplying the whole of the UK, this means tracking two live versions of the same underlying compositional and labelling framework: the GB-adapted retained law, which a UK body can amend independently of the EU going forward, and the directly applicable EU regulation (as it is amended in Brussels) in Northern Ireland. A label or compositional change adopted in one jurisdiction does not automatically apply in the other, and notification under Article 9 needs to go to the right competent authority for each market the product is placed in.
10Why medical food manufacturing runs food GMP plus tighter specification control
Because medical foods and FSMP are legally foods, their manufacturing sits under food current good manufacturing practice rather than pharmaceutical GMP — in the US, that means 21 CFR Part 117, Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food, rather than drug cGMP under 21 CFR Parts 210/211. There is no regulatory requirement to run a drug-grade quality system, and no FDA facility registration category specific to "medical food manufacturer" distinct from other human food facilities.
In practice, responsible medical-food and FSMP manufacturers layer controls on top of baseline food GMP that go well beyond what a conventional packaged-food line needs, because the population consuming the product is clinically vulnerable and the formulation's entire rationale is a specific, often narrow, nutrient profile: nutrient-content specification testing tighter than standard food labelling tolerances, because a product formulated to restrict or supply a specific amino acid or micronutrient for a metabolic disorder can cause real clinical harm if the actual content drifts materially from label claim in either direction; batch-to-batch consistency verification and retained samples, since the product may be a patient's sole source of nourishment for an extended period; full lot traceability from raw material through finished pack, so that a supplier-level contamination or an out-of-specification nutrient result can be traced to every affected lot and every account that received it, supporting a targeted recall rather than a blanket one; and tight label and artwork control, because FSMP and medical-food labelling carries legally mandated warning statements ("use under medical supervision" in the EU/UK framework, the medical-food/dietary-supplement distinction in the US) that must stay correct across label revisions, SKU variants, and — for UK/EU supply — across the GB and Northern Ireland label versions described above.
None of this converts the product into a drug or creates a regulatory requirement equivalent to validated pharmaceutical batch release; the compositional specification control, lot traceability, and label-version discipline described here are quality-management practices manufacturers adopt to manage clinical risk and support their own classification position, not statutory add-ons to 21 CFR Part 117 or to the EU's Regulation 609/2013 framework.
Frequently asked questions
Q.Is a medical food the same thing as a dietary supplement in the US?+
No. Dietary supplements are regulated under the Dietary Supplement Health and Education Act framework, can be sold without physician involvement, and cannot claim to treat or manage a specific disease without becoming an unapproved drug claim. Medical food is a separate statutory category under the Orphan Drug Act (21 U.S.C. 360ee(b)(3)) and 21 CFR 101.9(j)(8), built specifically around disease-specific dietary management under active medical supervision. FDA's warning letters repeatedly target products marketed as medical foods that, on the facts, look more like supplements sold at retail without that supervision element.
Q.Does FDA approve medical foods before they go on sale?+
No. Medical foods are regulated as foods, not drugs, so there is no FDA premarket approval, clearance, or authorisation process equivalent to a New Drug Application or a 510(k). The manufacturer is responsible for determining, against the statutory and regulatory definitions, that its product qualifies as a medical food; FDA's role is largely after-the-fact, through facility inspection and labelling review.
Q.What are the three FSMP compositional categories under EU/UK law?+
Commission Delegated Regulation (EU) 2016/128, Article 2, splits FSMP into: nutritionally complete food with a standard formulation (can be a sole source of nourishment); nutritionally complete food with a disease-specific nutrient-adapted formulation (can also be a sole source of nourishment); and nutritionally incomplete food, which is not suitable as a sole source of nourishment regardless of formulation type.
Q.Do I need to notify a regulator before selling FSMP in the UK or EU?+
Yes, but it is a notification, not an approval. Article 9 of Delegated Regulation (EU) 2016/128 requires the food business operator to notify the relevant competent authority — in Great Britain, the Secretary of State, Welsh Ministers, or the Scottish competent authority depending on where the product is marketed; in Northern Ireland, under the directly applicable EU regime — by sending a label model and any further information reasonably requested to establish compliance.
Q.Why does FSMP labelling in Northern Ireland sometimes differ from Great Britain?+
Post-Brexit, Regulation (EU) No 609/2013 and Delegated Regulation (EU) 2016/128 apply in Great Britain as retained EU law, which UK competent authorities can now amend independently of Brussels. Under the Windsor Framework, EU nutrition legislation continues to apply directly in Northern Ireland, following the EU's own amendments rather than the GB-adapted text. A manufacturer supplying all four UK nations needs to track both versions and notify the correct competent authority for each.
Q.What GMP framework applies to medical food and FSMP manufacturing?+
Food current good manufacturing practice — 21 CFR Part 117 in the US — rather than pharmaceutical GMP. Because the product's nutritional rationale is disease-specific and the consuming population is clinically vulnerable, manufacturers commonly add tighter specification testing, batch retains, full lot traceability, and strict label-version control on top of the baseline food GMP requirement, but these are quality-management choices rather than a distinct statutory manufacturing standard.
Primary sources
- FDA — Medical Foods Guidance Documents & Regulatory Information
- eCFR — 21 CFR 101.9, Nutrition labeling of food
- FDA Warning Letter — Accera, Inc. (Axona), 26 December 2013
- FDA Warning Letter — ND Labs, Inc., 1 September 2017 (hosted copy)
- FDA — Guidance for Industry: Frequently Asked Questions About Medical Foods, Second Edition (May 2016, hosted copy)
- EUR-Lex — Regulation (EU) No 609/2013
- EUR-Lex — Summary of Regulation (EU) No 609/2013
- EUR-Lex — Commission Delegated Regulation (EU) 2016/128
- EUR-Lex — Consolidated text 02016R0128 (15.07.2021)
- EUR-Lex — Summary of Delegated Regulation (EU) 2016/128 (foods for special medical purposes)
- EUR-Lex — Commission Notice on the classification of Food for Special Medical Purposes (2017/C 401/01)
- legislation.gov.uk — Delegated Regulation (EU) 2016/128, Article 9 (GB notification)
- legislation.gov.uk — Regulation (EU) No 609/2013, Article 1 and 2 (GB text)
- GOV.UK — Nutrition legislation information sheet
Further reading
- 21 CFR Part 117The food current good manufacturing practice and preventive-controls rule that applies to medical food manufacturing facilities.
- EU Novel Food Regulation (EU) 2015/2283A related EU food-law authorisation regime, useful for contrasting notification-only FSMP with a genuine premarket approval pathway.
- UK Food Supplements Regulations 2003The UK supplement framework that sits next to, and is sometimes confused with, the medical food/FSMP category.
- FDA Warning LetterHow FDA's warning-letter process works generally, including the misbranding findings used against mis-marketed medical foods.
- Certificate of analysis (CoA)The per-lot nutrient and specification record that underpins the tighter compositional control FSMP manufacturers typically run.
Want to see how Medical Food (US) and FSMP (EU) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
